Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
[Paper-level Aggregated] PMCID: PMC1952070
Evidence Type(s): Oncogenic, Predictive
Justification: Oncogenic: The L858R mutation in exon 21 is a well-known oncogenic mutation associated with non-small cell lung cancer and has been previously correlated with gefitinib sensitivity, although in this study it was found in a non-responder. Predictive: The presence of mutations in the EGFR tyrosine kinase domain, including L858R, has been previously associated with response to gefitinib, indicating a potential predictive value for treatment outcomes.
Gene→Variant (gene-first): TXK(7294):G/A NA:rs10251977 NA:rs17290643 EGFR(1956):L858R EGFR(1956):T790M
Genes: TXK(7294) NA EGFR(1956)
Variants: G/A rs10251977 rs17290643 L858R T790M